Bli medlem
Bli medlem

Du är här


Nominations Committee for the 2017 AGM in PledPharma AB

or the 2017 AGM in PledPharma AB

Stockholm, 2016-10-31 10:06 CET (GLOBE NEWSWIRE) --
The Chairman of PledPharma AB has established a Nomination Committee for the
Annual General Meeting that is to be held on April 25, 2017.

The Nomination Committee consists of Staffan Persson, Peter Lindell and Astrid
Samuelsson. The members of the Nomination Committee have been appointed by
PledPharma’s three major shareholders. The Nomination Committee has elected
Staffan Persson as convener for the Committee. Håkan Åström (Chairman of
PledPharma) has been co-opted to the Nomination Committee.

The Committee's task is to present to the Annual General Meeting proposals
regarding Chairman and other members of the board as well as fees and other
remuneration to the Board´s members. The Nomination Committee shall also submit
proposals for appointment and remuneration of auditors. Further, the Committee
shall submit proposals to the process to appoint the Nomination Committee for
the AGM in 2018.

Shareholders who wish to submit proposals to the Nomination Committee can do so
by email:

For more information please contact:

Håkan Åström, Chairman, phone: +46 703 747 213

Jacques Näsström, CEO, phone: +46 737 130 979

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® reduces nerve damage
associated with chemotherapy and positive results from the Phase IIb study
PLIANT were presented during the spring of 2015. The drug candidate Aladote® is
being developed to reduce the risk of acute liver failure associated with
acetaminophen poisoning.

PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the
company’s Certified Adviser (tel +46 8 463 80 00). For more information, see

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.